Antibodies That Specifically Bind To TL1A

ABSTRACT

Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn&#39;s disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/220,442, filed on Sep. 18, 2015, the contents of which are incorporated by reference herein, in their entirety and for all purposes.

REFERENCE TO A SEQUENCE LISTING

This application includes a Sequence Listing submitted electronically as a text file named TL1A_ST25, created on Sep. 18, 2015 with a size of 89,000 bytes. The Sequence Listing is incorporated by reference herein.

FIELD OF THE INVENTION

This disclosure relates generally to the field of antibody engineering. More specifically, this disclosure relates to variant antibodies that bind specifically to TL1A, and which inhibit the interaction between TL1A and the death receptor 3 (DR3). In some aspects, the antibodies also inhibit the interaction between TL1A and the decoy receptor 3 (DcR3). The antibodies have improved potency relative to the parent antibody from which the variants were derived.

BACKGROUND OF THE INVENTION

Various publications, including patents, published applications, accession numbers, technical articles and scholarly articles are cited throughout the specification. Each of these cited publications is incorporated by reference, in its entirety and for all purposes, in this document.

TNF-like ligand 1A (TL1A, syn. TNF superfamily member 15 (TNFSF15); TL1 and VEGI) is a member of the tumor necrosis factor superfamily, which is expressed by antigen presenting cells (including dendritic cells, B cells and macrophages), CD4+ and CD8+ T cells and endothelial cells. TL1A can be expressed on the cell surface or secreted as a soluble cytokine. The receptor for TL1A, Death Receptor 3 (DR3) is expressed by a variety of cells, including CD4+ and CD8+ T cells, NK cells, NKT cells and FOXP3+ regulatory T (Treg) cells and type-2 and type-3 innate lymphoid cells (ILC2 and ILC3).

TL1A can also bind a decoy receptor (DcR3), which is a competitive inhibitor of DR3. DcR3 also acts as a decoy receptor for Fas-ligand (Fas-L) and lymphotoxin-like inducible protein that competes with glycoprotein D for binding herpesvirus entry mediator on T-cells (LIGHT). Accordingly, DcR3 is an important regulator of several signal transduction pathways.

The TL1A/DR3 signalling pathway has been implicated in several biological systems, which are associated with human diseases. For example, TL1A has been shown to play a role in immunity, angiogenesis, and homeostasis of barrier tissues. Inhibiting TL1A interaction with DR3 also has been shown to promote a therapeutic benefit in several immune-mediated conditions, such as experimental autoimmune encephalomyelitis (EAE; a model of multiple sclerosis), colitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, skin disease, asthma and arthritis.

Accordingly, compounds that inhibit TL1A activity are desirable, e.g., for their therapeutic, prophylactic, diagnostic and prognostic uses.

SUMMARY OF THE INVENTION

Provided herein is a recombinant antibody comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 30, provided that when the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2.

In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 20. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 23, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 25, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 26, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21 and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 25, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 26, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22. In some aspects, the antibody comprises a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 27.

Also provided herein is a recombinant antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14, provided that when the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. In some aspects, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10.

In some aspects, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 60. In some aspects, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 61. In some aspects, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain comprising the amino acid sequence of SEQ ID NO: 61.

Such recombinant antibodies preferably are full length, and preferably are monoclonal. Such recombinant antibodies bind to TL1A with enhanced affinity relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. Such recombinant antibodies have enhanced potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 10-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 12-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 13-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 15-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 20-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 25-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 27-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 40-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. Fold-enhancement of potency may be determined according to a TL1A-induced caspase potency assay in TF-1 cells.

Such recombinant antibodies may comprise a human IgG1 heavy chain constant region, a human IgG2 heavy chain constant region, or a human IgG4 heavy chain constant region, or any allotypes thereof. The human IgG1 heavy chain constant region may comprise SEQ ID NO: 42, or SEQ ID NO: 43 (human IgG1 ΔK), or SEQ ID NO: 44 (human IgG1 with YTE), or SEQ ID NO: 64 (human IgG1 with YTE and ΔK), or SEQ ID NO: 63 (human IgG1 with L234A, L235A, G237A) or SEQ ID NO: 62 (human IgG1 with L234A, L235A, G237A and ΔK), or SEQ ID NO: 65 (human IgG1 with L235A and G237A) or SEQ ID NO: 66 (human IgG1 with L235A, G237A and ΔK). The human IgG2 heavy chain constant region may comprise SEQ ID NO: 67, or SEQ ID NO: 70 (human IgG2 ΔK), or SEQ ID NO: 71 (human IgG2 with A330S, P331S), or SEQ ID NO: 68 (human IgG2 with A330S, P331S and ΔK). The human IgG4 heavy chain IgG4 constant region may comprise SEQ ID NO: 45, or SEQ ID NO: 46 (human IgG4 with S228P and AK), or SEQ ID NO: 47 (human IgG4 with S228P and YTE), or SEQ ID NO: 69 (human IgG4 with S228P, YTE and ΔK). It will be understood that an IgG4 heavy chain could be used without the stabilizing substitution S228P (e.g., IgG4 with YTE alone, or IgG4 with YTE and ΔK, or IgG4 with ΔK alone).

The recombinant antibodies may comprise a human lambda light chain constant region or an allotype thereof. The human light chain lambda constant region may comprise SEQ ID NO: 48.

Such recombinant antibodies bind to human TL1A, and may bind to the TL1A of a non-human primate, or the TL1A of a non-human mammal such as a mouse, rat, guinea pig, cat, dog, rabbit, or pig.

Such recombinant antibodies may be used in a method for treating a respiratory tract disease, a method for treating a gastrointestinal disease, a method of treating a skin disease, or a method of treating arthritis, or may be for use in the treatment of a respiratory tract disease, a gastrointestinal disease, a skin disease, or arthritis, or may be for use in the manufacture of a medicament for the treatment of a respiratory tract disease, a gastrointestinal disease, a skin disease, or arthritis. The respiratory tract disease may comprise one or more of asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary sarcoidosis, allergic rhinitis, or cystic fibrosis. The gastrointestinal disease may comprise one or more of inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, or irritable bowel syndrome, or a gastrointestinal disease or condition associated with cystic fibrosis. The arthritis may comprise rheumatoid arthritis. The skin disease may comprise one or more of atopic dermatitis, eczema, and scleroderma.

Human subjects, non-human primate subjects, or non-human mammalian subjects in need of such treatments may be treated with the antibodies or a composition comprising the antibodies, for example, by administering the antibodies or composition thereof to the subject. Administration may be parenteral, for example, subcutaneous and/or intravenous.

Such recombinant antibodies may be used in a method for detecting TL1A on the surface of peripheral blood mononuclear cells (PBMCs). The methods comprise contacting an antibody that binds to TL1A as described or exemplified herein with PBMCs obtained from a subject, and detecting the antibody bound to TL1A on the surface of the PBMCs. The methods may further comprise quantifying the level of TL1A on the PBMCs. The methods may further comprise obtaining the PBMCs from the subject.

Such recombinant antibodies may be used in a method for detecting TL1A in blood serum. The methods comprise contacting an antibody that binds to TL1A as described or exemplified herein with blood serum obtained from a subject, and detecting the antibody bound to TL1A in the serum. The methods may further comprise quantifying the level of TL1A in the blood serum. The methods may further comprise obtaining the serum from blood obtained from the subject. The methods may further comprise obtaining blood from the subject.

Polynucleotides encoding one or more of the heavy chain variable region and the light chain variable region of such antibodies are provided. The polynucleotides may further encode a heavy chain constant region and/or a light chain constant region.

In some aspects, a polynucleotide comprises a nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, for example, a nucleic acid sequence comprising SEQ ID NO: 51 or SEQ ID NO: 58. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 2, for example, a nucleic acid sequence comprising SEQ ID NO: 50. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, for example, a nucleic acid sequence comprising SEQ ID NO: 52 or SEQ ID NO: 59. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 6, for example, a nucleic acid sequence comprising SEQ ID NO: 54. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, for example, a nucleic acid sequence comprising SEQ ID NO: 55. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 8, for example, a nucleic acid sequence comprising SEQ ID NO: 56. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 10, for example, a nucleic acid sequence comprising SEQ ID NO: 57.

In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, for example, a nucleic acid sequence comprising SEQ ID NO: 49. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, for example, a nucleic acid sequence comprising SEQ ID NO: 52. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 5, for example, a nucleic acid sequence comprising SEQ ID NO: 53. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 6, for example, a nucleic acid sequence comprising SEQ ID NO: 54. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 7, for example, a nucleic acid sequence comprising SEQ ID NO: 55. In some aspects, the polynucleotide comprises a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 8, for example, a nucleic acid sequence comprising SEQ ID NO: 56.

Vectors comprising one or more of such polynucleotides are provided. Cells transformed with one or more such polynucleotides or such vectors are provided. Transformed cells may be mammalian, and preferably are mammalian expression host cells such as CHO cells, NS0 cells, or HEK293 cells.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the positions and identities of each of the single amino acid substitutions made to the CDR1 or CDR2 regions or to selected amino acid residues adjacent to CDR2 of the parent antibody (320-179) variable heavy chain. Boxed regions represent the CDRs according to the AbM numbering system.

FIG. 2 shows the positions and the identities of each of the single amino acid substitutions made to the CDR1 or CDR3 regions of the parent antibody (320-179) variable light chain. Boxed regions represent the CDRs according to the AbM numbering system.

FIG. 3 shows an alignment of variant anti-TL1A-antibody heavy chains.

FIG. 4 shows an alignment of variant anti-TL1A-binding antibody light chains.

FIG. 5 shows a comparison of the TL1A dissociation phase of variant anti-TL1A antibodies, as measured by SPR.

FIG. 6 shows the results of TF-1 cell caspase potency assays with variant TL1A antibodies.

FIG. 7 shows the results of TF-1 cell caspase potency assays using various TL1A antibodies compared to the parent antibody, 320-179.

FIG. 8 shows that antibody 320-587 has superior TL1A potency in a TF-1 cell caspase potency assay, compared to other published anti-TL1A antibodies across several different experiments.

FIG. 9 shows various anti-TL1A antibodies that inhibit TL1A binding to DR3, as compared to an isotype control as measured in ELISA format.

FIG. 10 shows that the parent antibody, 320-179, does not inhibit TL1A binding to DcR3 while the variant anti-TL1A antibodies do inhibit the TL1A-DcR3 interaction.

FIG. 11 shows that antibody 320-587 cross reacts with and binds to TL1A of different species; the antibody bound to TL1A from all species tested.

FIG. 12 shows the results of the administration of antibody 320-587 in a rat TNBS-induced colitis model, demonstrating that the antibody significantly ameliorates symptoms of colitis

FIG. 13 shows that antibody 320-587 detects human TL1A secreted from human PBMCs stimulated with immune complexes, in an ELISA test.

FIG. 14 shows that antibody 320-587 detects a population of human PBMCs that express membrane TL1A on their surface, in a flow cytometry test.

FIG. 15 shows that rats having acute OVA-induced asthma treated with antibody 320-587 had significantly reduced eosinophils in the bronchoalveolar lavage fluid (BALF).

FIGS. 16A through 16D show treatment of guinea pigs having acute OVA-induced asthma treated with antibody 320-587 had improvements in (FIG. 16A) BALF eosinophils, (FIG. 16B) BALF macrophages, (FIG. 16C) Airways hyper responsiveness after early asthmatic reaction, and (FIG. 16D) Magnitude of early asthmatic reaction.

FIGS. 17A through 17E show treatment of rats having chronic OVA-induced asthma treated with antibody 320-587 had improvements in (FIG. 17A) BALF eosinophils, (FIG. 17B) BALF macrophages, (FIG. 17C) BALF IL-13, (FIG. 17D) goblet cell hyperplasia as assessed by PAS reactivity, and (FIG. 17E) mucosal thickening as assessed from H&E stained sections.

FIG. 18 shows the dose of ovalbumin required to double airways obstruction.

FIG. 19 shows treatment of rats having TNBS-induced colitis treated with antibody 320-587 had improvements in ulcer area fibrosis.

FIGS. 20A through 20E show a comparison of rats having TNBS-induced colitis with DNBS-induced colitis, treated with antibody 320-587 and the effects at 7 and 14 days, on (FIG. 20A) colon weight/length ratio, (FIG. 20B) colon fibrosis, (FIG. 20C) colon infiltrate, and (FIG. 20D) colon damage. FIG. 20E shows representative sections of ulcer area at 7 and 14 days.

FIGS. 21A through 21C show treatment of rats having DSS-induced colitis treatment with antibody 320-587 had improvements in (FIG. 21A) weight change during DSS administration, (FIG. 21B) Clinical scoring during DSS administration, and (FIG. 21C) colon weight/length ratio.

FIG. 22 shows changes in TL1A-induced intraperitoneal cytokines in response to 320-587 treatment.

DETAILED DESCRIPTION OF THE INVENTION

Various terms relating to aspects of disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided herein.

The terms “subject” and “patient” are used interchangeably and include any animal. Mammals are preferred, including companion (e.g., cat, dog) and farm mammals (e.g., pig, horse, cow), as well as rodents, including mice, rabbits, and rats, guinea pigs, and other rodents. Non-human primates, such as cynomolgus monkeys, are more preferred, and human beings are highly preferred.

A molecule such as an antibody has been “isolated” if it has been altered and/or removed from its natural environment by the hand of a human being.

As used herein, the singular forms “a,” “an,” and “the” include plural referents unless expressly stated otherwise.

“Specificity” in the context of antibody-antigen interactions is not necessarily an absolute designation but may constitute a relative term signifying the degree of selectivity of an antibody for an antigen-positive cell compared to an antigen-negative cell. Specificity of an antibody for an antigen-positive cell is mediated by the variable regions of the antibody, and usually by the complementarity determining regions (CDRs) of the antibody. A construct may have from about 100 to about 1000-fold specificity for antigen-positive cells compared to antigen-negative cells.

As used herein, the term “recombinant” includes the expression from genes made by genetic engineering or otherwise by laboratory manipulation.

The disclosure provides variant anti-TL1A antibodies comprising a recombinantly altered heavy and/or light chain variable region of antibody 320-179, which variant antibodies specifically bind to TL1A. These 320-179 variant antibodies inhibit the capability of TL1A to interact with DR3 and, in some aspects, also with DcR3 and, further inhibit the signalling induced by the interaction of TL1A with DR3. These antibodies have enhanced potency relative to antibody 320-179. These antibodies have enhanced affinity for TL1A relative to antibody 320-179.

The enhanced potency may be at least about 10-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 12-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 13-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 15-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 20-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 25-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 27-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. The enhanced potency may be at least about 40-fold greater potency relative to an antibody having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. Fold-enhancement of potency may be determined, for example, by measuring caspase release in TL1A-induced apoptosis in a TF-1 cell assay.

The 320-179 variant antibodies are recombinantly expressed, and specifically bind to TL1A. The parent antibody, 320-179, comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. In some aspects, a 320-179 variant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14, provided that when the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2. The 320-179 variant antibody is capable of inhibiting the interaction of TL1A with DR3. The 320-179 variant antibody has enhanced potency relative to antibody 320-179 and/or has enhanced affinity for TL1A relative to antibody 320-179.

In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 5. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 7. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8. In some highly preferred aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 7. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8. In some aspects, the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10.

In highly preferred aspects, the 320-179 variant antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4, and specifically binds to TL1A. In some aspects, the heavy chain variable region of SEQ ID NO: 3 is joined to a human IgG1(ΔK) heavy chain constant region (e.g., SEQ ID NO: 43) such that the heavy chain comprises SEQ ID NO: 60. In some aspects, the light chain variable region of SEQ ID NO: 4 is joined to a lambda human light chain constant region (e.g., SEQ ID NO: 48) such that the light chain comprises SEQ ID NO: 61. The 320-179 variant antibody is capable of inhibiting the interaction of TL1A with DR3. The variant antibody has enhanced potency relative to antibody 320-179 and/or has enhanced affinity for TL1A relative to antibody 320-179.

In some aspects, the 320-179 variant antibodies are recombinantly expressed and specifically bind to TL1A, and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17. The antibodies may comprise a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 30. In aspects where the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region preferably does not comprise the amino acid sequence of SEQ ID NO: 2. These 320-179 variant antibodies are capable of inhibiting the interaction of TL1A with DR3. These 320-179 variant antibodies have enhanced potency relative to antibody 320-179 and/or have enhanced affinity for TL1A relative to antibody 320-179.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 24, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 20.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 16, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 24, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 22.

In some aspects, the antibodies specifically bind to TL1A and comprise a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 18, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 27.

In some aspects, the antibodies specifically bind to TL1A, and comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region, provided that the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2. In some aspects, the antibodies specifically bind to TL1A, and comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region or a light chain. The light chain variable region may further comprise a lambda constant region.

In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2 and a heavy chain variable region, provided that the heavy chain variable region does not comprise the amino acid sequence of SEQ ID NO: 1. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a heavy chain variable region. In some aspects, the antibodies specifically bind to TL1A, and comprise a light chain variable region comprising the amino acid sequence of SEQ ID NO: 14 and a heavy chain variable region, provided that if the light chain variable region comprises the amino acid sequence of SEQ ID NO: 2, the heavy chain variable region does not comprise the amino acid sequence of SEQ ID NO: 1. The heavy chain variable region may further comprise a heavy chain constant region, including any IgG1, IgG2, or IgG4 heavy chain constant region amino acid sequence described or exemplified herein.

The 320-179-variant antibodies specifically bind to TL1A. The antibodies bind to human TL1A, and may bind to one or more of cynomolgus monkey TL1A, mouse TL1A, rat TL1A, guinea pig TL1A, cat TL1A, dog TL1A, pig TL1A, or rabbit TL1A. In some aspects, the antibodies may bind to TL1A of multiple different species, for example, if the epitope is shared. In some aspects, human TL1A comprises the amino acid sequence of SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO: 33. In some aspects, cynomolgus monkey TL1A comprises the amino acid sequence of SEQ ID NO: 34. In some aspects, mouse TL1A comprises the amino acid sequence of SEQ ID NO: 35. In some aspects, rat TL1A comprises the amino acid sequence of SEQ ID NO: 36. In some aspects, guinea pig TL1A comprises the amino acid sequence of SEQ ID NO: 37. In some aspects, cat TL1A comprises the amino acid sequence of SEQ ID NO: 38. In some aspects, pig TL1A comprises the amino acid sequence of SEQ ID NO: 39. In some aspects, rabbit TL1A comprises the amino acid sequence of SEQ ID NO: 40. In some aspects, dog TL1A comprises the amino acid sequence of SEQ ID NO: 41.

The 320-179-variant antibodies have a binding affinity for an epitope on TL1A that includes an equilibrium dissociation constant (K_(D)), which can be measured according to a kinetic exclusion assay, such as a KINEXA® assay (Sapidyne Instruments Inc., Boise, Id.). The K_(D) for TL1A binding determined from a kinetic exclusion assay is preferably less than about 1000 pM. In some aspects, the K_(D) for TL1A binding determined from a kinetic exclusion assay is less than about 500 pM, or less than about 400 pM, or less than about 300 pM, or less than about 200 pM. In some preferred aspects, the K_(D) for TL1A binding determined from a kinetic exclusion assay is less than about 100 pM.

The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 10 pM to about 100 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 25 pM to about 75 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 30 pM to about 60 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 30 pM to about 50 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 35 pM to about 50 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 36 pM to about 46 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 38 pM to about 44 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 39 pM to about 43 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 40 pM to about 45 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may be from about 35 pM to about 42 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may about 40 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may about 41 pM. The K_(D) for TL1A binding determined from a kinetic exclusion assay may about 42 pM. The kinetic exclusion assay may use the antibody molecule or TL1A molecule as the constant binding partner, and the other molecule as the titrant.

The 320-179-variant anti-TL1A antibodies are preferably capable of binding to TL1A-positive cells. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 100 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 75 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 50 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 30 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 25 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 20 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 18 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 15 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 13 nM. The antibody may bind to a TL1A-positive cell with an EC₅₀ value of less than about 10 nM.

The 320-179-variant antibodies preferably are monoclonal, and more preferably are full length antibodies comprising two heavy chains and two light chains. In some aspects, the antibodies comprise derivatives or fragments or portions of antibodies that retain the antigen-binding specificity, and also preferably retain most or all of the affinity, of the 320-179 parent antibody molecule (e.g., for TL1A). For example, derivatives may comprise at least one variable region (either a heavy chain or light chain variable region). Other examples of suitable antibody derivatives and fragments include, without limitation, antibodies with polyepitopic specificity, bispecific antibodies, multi-specific antibodies, diabodies, single-chain molecules, as well as FAb, F(Ab′)2, Fd, Fabc, and Fv molecules, single chain (Sc) antibodies, single chain Fv antibodies (scFv), individual antibody light chains, individual antibody heavy chains, fusions between antibody chains and other molecules, heavy chain monomers or dimers, light chain monomers or dimers, dimers consisting of one heavy and one light chain, and other multimers. Single chain Fv antibodies may be multi-valent. All antibody isotypes may be used to produce antibody derivatives, fragments, and portions. Antibody derivatives, fragments, and/or portions may be recombinantly produced and expressed by any cell type, prokaryotic or eukaryotic.

In a full-length antibody, each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. Typically, the antigen binding properties of an antibody are less likely to be disturbed by changes to FR sequences than by changes to the CDR sequences. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

The 320-179-variant antibodies are fully human. Fully human antibodies are those where the whole molecule is human or otherwise of human origin, or includes an amino acid sequence identical to a human form of the antibody. Fully human antibodies include those obtained from a human V gene library, for example, where human genes encoding variable regions of antibodies are recombinantly expressed. Fully human antibodies may be expressed in other organisms (e.g., mice and xenomouse technology) or cells from other organisms transformed with genes encoding human antibodies. Fully human antibodies may nevertheless include amino acid residues not encoded by human sequences, e.g., mutations introduced by random or site directed mutations.

In some aspects, the 320-179-variant antibodies may comprise non-immunoglobulin derived protein frameworks. For example, reference may be made to (Ku & Schutz, 1995, Proc. Natl. Acad. Sci. USA 92: 6552-6556) which describes a four-helix bundle protein cytochrome b562 having two loops randomized to create CDRs, which have been selected for antigen binding.

The 320-179-variant antibodies may comprise post-translational modifications or moieties, which may impact antibody activity or stability. These modifications or moieties include, but are not limited to, methylated, acetylated, glycosylated, sulfated, phosphorylated, carboxylated, and amidated moieties and other moieties that are well known in the art. Moieties include any chemical group or combinations of groups commonly found on immunoglobulin molecules in nature or otherwise added to antibodies by recombinant expression systems, including prokaryotic and eukaryotic expression systems.

Examples of side chain modifications contemplated by the disclosure include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH₄; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH₄.

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal. The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivation, for example, to a corresponding amide. Sulfydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of mixed disulfides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulfonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH. Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulfenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative. Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.

The 320-179-variant antibodies may include modifications that modulate serum half-life and biodistribution, including without limitation, modifications that modulate the antibody's interaction with the neonatal Fc receptor (FcRn), a receptor with a key role in protecting IgG from catabolism, and maintaining high serum antibody concentration. Serum half-life modulating modifications may occur in the Fc region of IgG1, IgG2, or IgG4, including the triple substitution of M252Y/S254T/T256E (the “YTE” substitutions, with numbering according to the EU numbering system (Edelman, G. M. et al. (1969) Proc. Natl. Acad. USA 63, 78-85)), as described in U.S. Pat. No. 7,083,784. Other substitutions may occur at positions 250 and 428, see e.g., U.S. Pat. No. 7,217,797, as well as at positions 307, 380 and 434, see, e.g., PCT Publ. No. WO 00/042072. Examples of constant domain amino acid substitutions which modulate binding to Fc receptors and subsequent function mediated by these receptors, including FcRn binding and serum half-life, are described in U.S. Publ. Nos. 2009/0142340, 2009/0068175, and 2009/0092599. Antibodies of any class may have the heavy chain C-terminal lysine omitted or removed to reduce heterogeneity (ΔK). The substitution of S228P (EU numbering) in the human IgG4 can stabilize antibody Fab-arm exchange in vivo (Labrin et al. (2009) Nature Biotechnology 27:8; 767-773), and this substitution may be present at the same time as the YTE and/or ΔK modifications.

The 320-179-variant antibodies comprise human constant domains. The heavy chain constant domains preferably are human IgG1, IgG2, or IgG4 constant domains. The light chain constant domains preferably are human lambda constant domains. A suitable human lambda domain comprises SEQ ID NO: 48.

Human heavy chain IgG1 constant regions that may be used with the 320-179 variant antibodies may be selected from among human IgG1 (SEQ ID NO: 42), human IgG1 (ΔK) (SEQ ID NO: 43), human IgG1 252Y/254T/256E (SEQ ID NO: 44), human IgG1 252Y/254T/256E (ΔK) (SEQ ID NO: 64), human IgG1 L234A/L235A/G237A (SEQ ID NO: 63), human IgG1 L234A/L235A/G237A (ΔK) (SEQ ID NO: 62), human IgG1 L235A/G237A (SEQ ID NO: 65), and human IgG1 L235A/G237A (ΔK) (SEQ ID NO: 66). Human heavy chain IgG2 constant regions that may be used with the 320-179 variant antibodies may be selected from among human IgG2 with or without ΔK (SEQ ID NO: 67 and SEQ ID NO: 70) and human IgG2 A330S/P331S with or without (ΔK) (SEQ ID NO: 71 and SEQ ID NO: 68). Human heavy chain IgG4 constant regions that may be used with the 320-179 variant antibodies may be selected from among human IgG4 S228P (SEQ ID NO: 45), human IgG4 S228P (ΔK) (SEQ ID NO: 46), human IgG4 228P/252Y/254T/256E (SEQ ID NO: 47), and human IgG4 228P/252Y/254T/256E (ΔK) (SEQ ID NO: 69).

The 320-179-variant antibodies may be labelled, bound, or conjugated to any chemical or biomolecule moieties. Labelled antibodies may find use in therapeutic, diagnostic, or basic research applications. Such labels/conjugates can be detectable, such as fluorochromes, electrochemiluminescent probes, quantum dots, radiolabels, enzymes, fluorescent proteins, luminescent proteins, and biotin. The labels/conjugates may be chemotherapeutic agents, toxins, isotopes, and other agents used for treating conditions such as the killing of cancer cells. Chemotherapeutic agents may be any which are suitable for the purpose for which the antibody is being used.

The antibodies may be derivatized by known protecting/blocking groups to prevent proteolytic cleavage or enhance activity or stability.

Polynucleotide sequences that encode antibodies and their subdomains (e.g., FRs and CDRs) are featured in the disclosure. Polynucleotides include, but are not limited to, RNA, DNA, cDNA, hybrids of RNA and DNA, and single, double, or triple stranded strands of RNA, DNA, or hybrids thereof. Polynucleotides may comprise a nucleic acid sequence encoding the heavy chain variable region and/or the light chain variable region of a 320-179 variant antibody as described or exemplified herein. Complements of the polynucleotide sequences are also within the scope of the disclosure.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 may comprise the nucleic acid sequence of SEQ ID NO: 50.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 4 may comprise the nucleic acid sequence of SEQ ID NO: 52.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 5. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 5 may comprise the nucleic acid sequence of SEQ ID NO: 53.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 6 may comprise the nucleic acid sequence of SEQ ID NO: 54.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 7. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 7 may comprise the nucleic acid sequence of SEQ ID NO: 55.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 8 may comprise the nucleic acid sequence of SEQ ID NO: 56.

A polynucleotide may comprise a nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 10. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 10 may comprise the nucleic acid sequence of SEQ ID NO: 57.

In some aspects, a polynucleotide comprises a first nucleic acid sequence encoding an antibody heavy chain variable region and a second nucleic acid sequence encoding an antibody light chain variable region. A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 may comprise the nucleic acid sequence of SEQ ID NO: 50.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 4 may comprise the nucleic acid sequence of SEQ ID NO: 52.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 6 may comprise the nucleic acid sequence of SEQ ID NO: 54.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 7 may comprise the nucleic acid sequence of SEQ ID NO: 55.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 8 may comprise the nucleic acid sequence of SEQ ID NO: 56.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 3 may comprise the nucleic acid sequence of SEQ ID NO: 51 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 10 may comprise the nucleic acid sequence of SEQ ID NO: 57.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 4. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 4 may comprise the nucleic acid sequence of SEQ ID NO: 52.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 5. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 5 may comprise the nucleic acid sequence of SEQ ID NO: 53.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 6 may comprise the nucleic acid sequence of SEQ ID NO: 54.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 7. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 7 may comprise the nucleic acid sequence of SEQ ID NO: 55.

A first nucleic acid sequence may encode an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8. A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 may comprise the nucleic acid sequence of SEQ ID NO: 49 and a polynucleotide encoding the amino acid sequence of SEQ ID NO: 8 may comprise the nucleic acid sequence of SEQ ID NO: 56.

In some aspects, a polynucleotide comprises a first nucleic acid sequence encoding an antibody heavy chain variable region and a second nucleic acid sequence encoding a heavy chain constant region. In preferred aspects, a polynucleotide comprises a first nucleic acid sequence encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a second nucleic acid sequence encoding an IgG1(ΔK) heavy chain constant region of SEQ ID NO: 43, for example, a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 58.

In some aspects, a polynucleotide comprises a first nucleic acid sequence encoding an antibody light chain variable region and a second nucleic acid sequence encoding a light chain constant region. In preferred aspects, a polynucleotide comprises a first nucleic acid sequence encoding an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a second nucleic acid sequence encoding a lambda light chain constant region of SEQ ID NO: 48, for example, a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 59.

Any of the polynucleotides described or exemplified herein may be comprised within a vector. Thus, vectors comprising polynucleotides are provided as part of the disclosure. The vectors may be expression vectors. Recombinant expression vectors containing a sequence encoding a polypeptide of interest are thus provided. The expression vector may contain one or more additional sequences, such as but not limited to regulatory sequences, a selection marker, a purification tag, or a polyadenylation signal. Such regulatory elements may include a transcriptional promoter, enhancers, mRNA ribosomal binding sites, or sequences that control the termination of transcription and translation.

Expression vectors, especially mammalian expression vectors, may include one or more nontranscribed elements, such as an origin of replication, a suitable promoter and enhancer linked to the gene to be expressed, other 5′ or 3′ flanking nontranscribed sequences, 5′ or 3′ nontranslated sequences (such as necessary ribosome binding sites), a polyadenylation site, splice donor and acceptor sites, or transcriptional termination sequences. An origin of replication that confers the ability to replicate in a specific host may also be incorporated.

The vectors may be used to transform any of a wide array of host cells well known to those of skill in the art, and preferably host cells capable of expressing antibodies. Vectors include without limitation, plasmids, phagemids, cosmids, bacmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), and baculovirus, as well as other bacterial, eukaryotic, yeast, and viral vectors. Suitable host cells include without limitation CHO cells, NS0 cells, HEK293 cells, or any eukaryotic stable cell line known or produced, and also include bacteria, yeast, and insect cells.

The antibodies may also be produced by hybridoma cells; methods to produce hybridomas being well known and established in the art.

The disclosure also provides compositions comprising the 320-179 variant antibodies. The compositions may comprise any of the antibodies described and/or exemplified herein and an acceptable carrier such as a pharmaceutically acceptable carrier. Suitable carriers include any media that does not interfere with the biological activity of the antibody and preferably is not toxic to a host to which it is administered. The compositions may be formulated for administration to a subject in any suitable dosage form.

The 320-179 variant antibodies may be used to treat a respiratory tract disease, a gastrointestinal disease, arthritis, or a skin disease in a subject. Thus, the disclosure features treatment methods. In general, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for a respiratory tract disease, gastrointestinal disease, arthritis, or a skin disease, such that the respiratory tract disease, gastrointestinal disease, arthritis, or skin disease is treated. The 320-179 variant antibody may comprise any antibody described or exemplified herein. Administering may comprise subcutaneously administering the antibody. Administering may comprise intravenously administering the antibody. The subject is preferably a human being. The subject may be a non-human primate such as a cynomolgus monkey, or may be a mammal such as a mouse, rat, guinea pig, cat, pig, rabbit, or dog.

In aspects where a respiratory tract disease is to be treated, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for a respiratory tract disease. The respiratory tract disease may comprise one or more of asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary sarcoidosis, allergic rhinitis, or cystic fibrosis. Thus, for example, in some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for asthma, such that the asthma is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for COPD, such that the COPD is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for pulmonary fibrosis, such that the pulmonary fibrosis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for pulmonary sarcoidosis, such that the pulmonary sarcoidosis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for allergic rhinitis, such that the allergic rhinitis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for cystic fibrosis, such that the cystic fibrosis is treated in the subject.

In aspects where a gastrointestinal disease is to be treated, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for a gastrointestinal disease. The gastrointestinal disease may comprise one or more of inflammatory bowel disease (IBD), Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome (IBS), eosinophilic esophagitis, or a gastrointestinal disease or condition associated with cystic fibrosis. Thus, for example, in some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for IBD, such that the IBD is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for Crohn's disease, such that the Crohn's disease is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for colitis, such that the colitis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for ulcerative colitis, such that the ulcerative colitis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for IBS, such that the IBS is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for eosinophilic esophagitis, such that the eosinophilic esophagitis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for a gastrointestinal disease or condition associated with cystic fibrosis, such that the gastrointestinal disease or condition associated with cystic fibrosis is treated in the subject.

In aspects where arthritis is to be treated, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for arthritis. The arthritis may comprise rheumatoid arthritis. Thus, for example, in some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for rheumatoid arthritis, such that the rheumatoid arthritis is treated in the subject.

In aspects where a skin disease is to be treated, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for a skin disease. The skin disease may comprise one or more of atopic dermatitis, eczema, or scleroderma. Thus, for example, in some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for atopic dermatitis, such that the atopic dermatitis is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for eczema, such that the eczema is treated in the subject. In some aspects, the methods comprise administering a 320-179 variant antibody, or composition thereof, to a subject in need of treatment for scleroderma, such that the scleroderma is treated in the subject.

The 320-179 variant antibodies described or exemplified herein may be used in the preparation of a medicament for use in the treatment of a respiratory tract disease. The 320-179 variant antibodies described or exemplified herein may be used in the preparation of a medicament for use in the treatment of a gastrointestinal disease. The 320-179 variant antibodies described or exemplified herein may be used in the preparation of a medicament for use in the treatment of arthritis. The 320-179 variant antibodies described or exemplified herein may be used in the preparation of a medicament for use in the treatment of a skin disease. The 320-179 variant antibodies described or exemplified herein may be used in the preparation of a medicament for use in the treatment of any one of asthma, COPD, pulmonary fibrosis, pulmonary sarcoidosis, allergic rhinitis, cystic fibrosis, inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, a gastrointestinal disease or condition associated with cystic fibrosis, arthritis, rheumatoid arthritis, atopic dermatitis, eczema, or scleroderma.

The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of a respiratory tract disease. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of a gastrointestinal disease. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of asthma. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of a skin disease. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of COPD. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of pulmonary fibrosis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of pulmonary sarcoidosis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of allergic rhinitis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of cystic fibrosis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of inflammatory bowel disease. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of Crohn's disease. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of colitis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of ulcerative colitis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of eosinophilic esophagitis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of a gastrointestinal disease or condition associated with cystic fibrosis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of irritable bowel syndrome. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of rheumatoid arthritis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of atopic dermatitis. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of eczema. The 320-179 variant antibodies described or exemplified herein may be for use in the treatment of scleroderma.

Also provided is an in vitro method for detecting TL1A in a tissue sample isolated from a subject, comprising contacting the antibody according to any one of claims 1-19 with a tissue sample isolated from a subject to form an antibody-TL1A complex, and detecting the complex in the tissue sample.

A 320-179 variant antibody may be used to detect TL1A-positive cells, for example, in a tissue sample obtained from a subject. The antibodies may be used to detect TL1A-positive peripheral blood mononuclear cells (PBMCs), for example, PBMCs obtained from a subject. The antibodies may be used to detect TL1A in the blood serum. Such methods may be carried out in vivo, ex vivo, in vitro, or in situ. In general, the methods comprise contacting any of the 320-179 variant antibodies described or exemplified herein with a tissue or cells, e.g., PBMCs, isolated from a subject to form an antibody-TL1A complex, and detecting the complex in the tissue or on the cells. The antibody may be labelled with a detectable label. The antibody may be detected with a secondary antibody that is labelled with a detectable label. The tissue may comprise or may be a biological fluid such as blood or blood serum. The tissue may comprise or may be respiratory tract tissue, such as lung tissue, sputum, bronchoalveolar lavage fluid, gastrointestinal tissue, or gastrointestinal lavage fluid. The tissue may comprise or may be skin or dermal tissue. The tissue may comprise or may be tissue of any joint in the body. The method may further comprise isolating the tissue from the subject. Such methods may be quantitative, for example, by quantifying the level of TL1A in the tissue, by quantifying the level of TL1A-positive cells, or by quantifying the level of TL1A on cells, or by quantifying the level of TL1A in the serum.

The disclosure also features kits comprising any of the 320-179 variant antibodies described and exemplified herein. The kits may be used to supply antibodies and other agents for use in diagnostic, basic research, or therapeutic methods, among others. In some aspects, the kits comprise any one or more of the 320-179 variant antibodies described or exemplified herein and instructions for using the one or more antibodies in a method for treating a respiratory tract disease, in a method for treating a gastrointestinal disease, or in a method for treating arthritis.

The following examples are provided to describe the disclosure in greater detail. They are intended to illustrate, not to limit, the disclosure.

Example 1 Materials and Methods

Amino acid positions in these examples are numbered according to the Kabat numbering system. CDRs are defined according to the AbM method of CDR definition system throughout this document.

1.1. Generation of variant bundles. The heavy- and light chain variable region amino acid sequences of antibody 320-179 (SEQ ID NOs: 1 and 2 respectively) were used as templates for the design of point variants. 320-179 has been previously described in U.S. Publ. No. 2014/0255302 (VH is SEQ ID NO: 186 and VL is SEQ ID NO: 199 in that publication) as 320-179 (also described as C320-179). This antibody had favorable biophysical properties, was a potent inhibitor of TL1A and had a low predicted immunogenicity profile.

Antibody variants of 320-179 were made by substituting one of a group of nine representative amino acids—A, S, Q, D, H, K, L, W, Y—one at a time at one of each CDR amino acid position (as defined by AbM nomenclature) in the light chain CDR1 (CDR-L1), the light chain CDR3 (CDR-L3), the heavy chain CDR1 (CDR-H1) and the heavy chain CDR2 (CDR-H2). Antibody variants, incorporating A, S, Q, D, H, K, L, W, Y, were also made at position 59 and 60 in the variable heavy chain and at position 79 in the variable light chain. A complete list of all single substituted antibody variants generated is shown in FIGS. 1 (variable heavy chain) and 2 (variable light chain), respectively.

1.2. Construction of Vectors Expressing Antibodies. Variable region variants were generated by back-translation of amino acid sequences into DNA sequences which were subsequently synthesized de novo by assembly of synthetic oligonucleotides. V_(H) variants were subcloned into a mammalian expression vector containing a human constant region to produce full-length antibody heavy chains (human IgG1 heavy chain C_(H)1, hinge, C_(H)2 and C_(H)3 domains) (e.g., UniProt No. P01857). Similarly, V_(L) variants were subcloned into a mammalian expression vector containing a human lambda light chain constant region to produce full-length antibody lambda chains (SwissProt No. P0CG05.1). In some instances, the full-length heavy chain and, separately, light chain, was back-translated into DNA sequences and subsequently synthesized de novo by assembly of synthetic oligonucleotides.

1.3. Expression of antibody variants. Antibodies were produced by co-transfecting antibody heavy- and light chains into EXP1293® cells (Life Technologies, Carlsbad, Calif.). The day before transfection, the number of cells needed for the experiment was determined. For each 20 mL transfection, 3.6×10⁷ cells were required in 20 mL of EXP1293® Expression Medium. On the day prior to transfection, cells were seeded at a density of 0.9×10⁶ viable cells/mL and incubated overnight at 37° C. in a humidified atmosphere of 8% CO₂ in air on an orbital shaker rotating at 200 rpm. On the day of transfection, the cell number and viability were determined using an automated cell counter. Only cultures with >98% viable cells were used. For each 20 mL transfection, lipid-DNA complexes were prepared by diluting 10 μg of heavy chain DNA and 10 μg of light chain DNA in OPTI-MEM® (Life Technologies, Carlsbad, Calif.) I Reduced Serum Medium (Cat. no. 31985-062) to a total volume of 1.0 mL. 54 μL of EXPIFECTAMINE® 293 Reagent (Life Technologies, Carlsbad, Calif.) was diluted in OPTI-MEM® I medium to a total volume of 1.0 mL. Both vials were mixed gently and incubated for 5 minutes at room temperature. Following incubation, the diluted DNA was mixed with the diluted EXPIFECTAMINE® 293 Reagent and the DNA-EXPIFECTAMINE® 293 Reagent mixture and incubated a further 20 minutes at room temperature to allow the formation of DNA-EXPIFECTAMINE® 293 Reagent complexes. Following incubation, 2 mL of DNA-EXPIFECTAMINE® 293 Reagent complex was added to each 50 mL bioreactor tube (TPP Techno Plastic Products AG). To the negative control tube, 2 mL of OPTI-MEM® (Life Technologies, Carlsbad, Calif.) I medium was added instead of DNA-EXPIFECTAMINE® 293 Reagent complex. The cells were incubated in a 37° C. incubator with a humidified atmosphere of 8% CO₂ in air on an orbital shaker rotating at 200 rpm. Approximately 16-18 hours post-transfection, 100 μL of EXPIFECTAMINE® 293 Transfection Enhancer 1 and 1.0 mL of EXPIFECTAMINE® 293 Transfection Enhancer 2 were added to each bioreactor. Antibodies were harvested at approximately 72 hours post-transfection.

1.4. Purification of antibody variants. Each antibody variant was expressed in EXPI293® cells in 20 mL of cell culture. Cultures were spun down in 50 mL falcon tubes at 3000×g for 20 minutes, and supernatants were filtered using a 0.22 μm filter (Corning). Supernatants were purified using a Gilson ASPEC GX274 robot. Briefly, SPE cartridges (Agilent, 12131014) packed with 1.2 mL MABSELECT SURE® protein A (GE Healthcare Bio-Sciences AB Uppsala, Sweden) resin were pre-equilibrated with 3 column volumes of 1×PBS. 18 mL of supernatant was run over the columns followed by a 4 ml 1×PBS wash. Each column was pre-eluted with 0.9 mL of 0.1 M citric acid, pH 2.9. Purified antibodies were eluted with 2 mL 0.1 M citric acid, pH 2.9. Antibodies were desalted into Sørensens PBS (59.5 mM KH₂PO₄, 7.3 mM Na₂HPO₄.2H₂O, 145.4 mM NaCl (pH ^(˜)5.8)) using PD-10 columns (GE Healthcare).

1.5. Antibody expression and antigen binding as determined by SPR. Using a CM5 sensor chip (GE Healthcare) Protein A (Pierce) was coupled to the chip surface using an amine coupling kit (GE Healthcare). Protein A was coupled on flow cell 1 and 2 (or alternatively 3 and 4) using a BIACORE® T200. Supernatants from EXPI-293® cells containing antibody or alternatively purified antibodies (as described in 1.4) were passed over the surface of flow cell 2, while buffer (HBS-EP) was passed over flow cell 1. The amount of supernatant or purified protein (as well as the concentration) injected during the capture stage varied between runs and is specified in the header of the Tables 3-11. At the end of injection of the supernatant or purified antibody the change in response units was measured. This value was reported as Capture Level in Tables 3-11. To determine if the antibody bound TL1A, the TL1A was then passed over flow cells 1 and 2 and the response units measured prior to the end of the injection of TL1A (the association phase). This value is labeled as TL1A Binding Level (Early) in Tables 3-11. The response units were measured prior to the end of the dissociation phase. This value is labeled as TL1A Binding Level (Late) in Tables 3-11 and is a measure of the amount of antibody that has been lost from the surface of the chip as a result of dissociation of the TL1A—antibody complex. The sensorgrams were double referenced (flow cell 2 is subtracted from flow cell 1 and a buffer blank). As there were a large number of antibody variants to screen, these were screened across different runs (Tables 3-11). In each case (except Run 3) the parent antibody, 320-179 was included in the run, for comparison purposes. A summary of the conditions used in each run is below:

TABLE 1 Approx- Conc. imate TL1A TL1A Binding TL1A Binding Run Super- capture sample Leval (Early) Level (Late) # natant Protein leval (RU) (ug/mL) timepoint timepoint Notes 1 x 400 10  59 590 Antibody diluted to 2 ug/mL, variable capture time 2 x 1000  10  44 220 Supernatant diluted into running buffer, variable capture times 2 x 400 10  44 590 Antibody diluted 2 ug/mL, variable capture time 3 x variable 10  59 590 Supernatant diluted into running buffer, 60 s capture 4 x 500 5 44 220 Antibody diluted to 2 ug/mL into running buffer 5 x 100 5 44 220 Supernatant diluted into running buffer, 6 x variable 5 44 170 Antibody diluted to 2 ug/mL into running buffer and captured for 45 s  7* x 400 5 44 220 Antibody diluted to approx. 2 ug/mL 8 x 400 5 44 590 Antibody diluted to 2 ug/mL, variable capture time 9 x 400 5 44 590 Antibody diluted to 2 ug/mL, variable capture time *This run was performed on a Biacore ® A100

The binding of anti-TL1A to different species TL1A was also determined using SPR. The anti-TL1A antibody was captured on the surface of a Protein A. TL1A from either human, rat, mouse, rabbit, guinea pig, pig, dog, cat or cynomolgus monkey were flowed over the surface and the response units measured.

1.6. Production of TL1A. Human TL1A was produced in the mammalian EXP1293® expression system, using a DNA expression construct coding for the extracellular domain (ECD) of human TL1A with an N-terminally located HIS and FLAG tag. Other species forms of TL1A were generated based on sequence listing on publically listed databases. These are summarized below:

TABLE 2 Species TL1A Public Database Reference SEQ ID NO: Human UniProt: O95150 31 Cynomolgus SEQ ID NO: 125 from 34 Monkey US Publ. No. 2014/0255302 Mouse UniProt: Q5UBV8 35 Rat UniProt: Q8K3Y7 36 Guinea Pig UniProt: H0VFN8 37 Cat NCBI: XP_003995828.1 38 Pig UniProt: 13LL00 39 Rabbit UniProt: G1T1T1 40 Dog UniProt: J9P221 41

Culture supernatant containing the secreted TL1A protein was harvested by centrifugation at 2000×g for 10 mins to remove the cells. The TL1A protein was purified from the supernatant using a HISTRAP® HP column (GE Healthcare). The eluted protein was buffer-exchanged into PBS using a HILOAD® 16/60 Superdex 200 prep grade column (GE Healthcare) and ^(˜)70 kDa fraction was separated by gel filtration on a HILOAD® 26/60 SUPERDEX® 200 prep grade column (GE Healthcare).

1.7. TF-1 Cell Line Potency Assay. To determine which anti-TL1A antibodies functionally neutralize the biological activity of TL1A, antibodies were tested for their ability to neutralize TL1A-induced apoptosis in a TF-1 cell line. The TF-1 human erythroleukemic cell line (ATCC: CRL-2003) was maintained in culture under standard conditions. TF-1 cells (7.5×10⁴/well) were incubated in black-sided 96-well plates (Greiner) with human TL1A 100 ng/ml and cycloheximide 10 μg/ml to induce apoptosis. Test antibodies at a concentration of 10 μg/mL (66.7 nM) or less were added to the plates and incubated for 4 to 5 hours. Induction of apoptosis was then assessed using the Homogeneous Caspases Kit (Roche) according to manufacturer's instructions.

Data were normalized by expression as a percentage of maximum apoptosis (apoptosis levels achieved by human TL1A plus cycloheximide in the absence of anti-TL1A antibody).

1.8. Receptor Selectivity of Lead Antibodies. TL1A binds both to its cognate signaling receptor, DR3, and to a decoy receptor, DcR3, which also serves as a decoy receptor for TNF family members Fas-L and LIGHT. Antibodies were assessed for their ability to inhibit binding of TL1A to its receptors in a competition ELISA. DR3/Fc Chimera (R&D Systems) or DcR3/Fc Chimera (R&D Systems) was coated onto a 96-well plate (Maxisorp, Nunc) at a concentration of 2 μg/ml. Serially diluted test antibodies were pre-incubated with single-site biotinylated human TL1A 1 μg/ml for 30 minutes then added to the DR3/Fc or DcR3/Fc coated wells. Bound TL1A was detected using streptavidin-horseradish peroxidase 1:2000 (BD Pharmingen). Data were normalized by expression as a percentage of maximum binding of TL1A to receptor in the absence of anti-TL1A antibody.

1.9. Kinetic Exclusion Assay. This assay measures the free concentration of one of the binding partners without perturbing the equilibrium. Solutions can be prepared off-line, using unmodified proteins in solution, and affinity measurements can be read days after mixing to ensure that equilibrium has been reached. In a kinetic exclusion assay, one interactant (termed the constant binding partner, or CBP) is held at a constant concentration, while the other (termed the titrant) is serially diluted. Kinetic exclusion assays may be used to determine the dissociation constant (K_(D)) and affinity of an antibody-antigen interaction. In a typical kinetic exclusion assay, the titrant is immobilized to beads (e.g., Sepharose or PMMA beads) and is used to capture the CBP free in solution. A secondary labeled probe is then used to quantify the amount of captured CBP. The kinetic exclusion assay is reviewed in Darling, R K et al. (2004) ASSAY and Drug Development Technol. 2(6):647-57.

The components were combined and allowed to reach equilibrium. The kinetic exclusion assay was then used to measure the free fraction of the CBP. Equilibrium curves with multiple CBP concentrations were analyzed using the n-curve analysis tool within the KinExA® Pro software (Version 4.1.11, Sapidyne) to obtain robust K_(D) determinations. The interaction of 320-587 for human TL1A was examined using two orientations: (1) CBP is 320-587, titrant is TL1A, and (2) CBP is TL1A, titrant is 320-587.

Example 2 Experimental Results

2.1. Selecting TL1A-binding variants with an equivalent or improved off-rate relative to C320-179. Variants of antibody 320-179 were constructed and expressed as described above. EXPI293® (Life Technologies Corp.) supernatants of each variant were assessed by BIACORE® (GE Healthcare) and the data obtained compared with that of the parental antibody 320-179. In some experiment the antibodies were purified using Protein A chromatography (See 1.4) and purified antibodies were used in BIACORE® (GE Healthcare) experiments. Tables 3-11 show the expression level of each variant, along with its binding to TL1A at an early and late time point. In later runs (Table 10 and 11) antibody variants containing more than one amino acid substitution were tested.

TABLE 3 SPR experiment - Run 1 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179  None None 410 140 117 320-184* None L79A 414 141 118 320-185* None L79S 401 137 114 320-186* None L79Q 398 136 113 320-187* None L79D 388 134 112 320-188* None L79H 397 136 113 320-189* None L79K 393 130 107 320-190* None L79W 395 136 113 320-191* None L79Y 408 140 117 *indicates antibodies that were selected for potency assay testing.

TABLE 4 SPR experiment - Run 2 - Anti-TL1A antibodies binding to TL1A. * indicates antibodies that were selected for potency assay testing. VH VL Substi- Substi- TL1A TL1A TL1A TL1A tution tution Binding Binding Binding Binding relative relative Capture Level Level Capture Level Level to 320- to 320- Leval (Early) (Late) Level (Early) (Late) Antibody 179 179 Supernatant Purified Antibody 320-179 None None 1133 287 261 410 140  117  320-192 None T24A  960 238 218 — — — 320-193 None T24S  990 249 227 409 103  91 320-194 None T24Q  974 247 226 398 76 64 320-195 None T24D  992 249 227 — — — 320-196 None T24H  995 250 228 — — — 320-197 None T24K 1017 255 232 401 105  94 320-198* None T24L 1023 262 241 — — — 320-199 None T24W 1050 251 233 404 97 85 320-200 None T24Y 1027 251 231 320-201* None S25A 990 274 252 393 73 57 320-202* None S25Q 1034 234 214 — — — 320-203 None S25D  977  61  24 407 65 35 320-204 None S25H 1003 193 155 — — — 320-205* None S25K 1025 290 271 401 70 51 320-206 None S25L 1000 257 235 — — — 320-207* None S25W 1022 268 243 — — — 320-208 None S25Y 1034 222 199 — — — 320-209* None S26A 1007 222 200 — — — 320-210 None S26Q 1033 225 202 — — — 320-211* None S26D 1025 206 164 392 80 64 320-212 None S26H 1013 226 205 — — — 320-213* None S26K 1052 218 194 422 79 65 320-214 None S26L 1038 221 196 — — — 320-215 None S26W 1021 220 199 — — — 320-216 None S26Y 1010 171 147 — — — 320-217 None S27A 1076 258 235 — — — 320-218 None S27Q 1081 239 218 412 92 80 320-219* None S27D 1061 243 220 — — — 320-220 None S27H 1049 253 230 — — — 320-221 None S27K 1063 225 207 413 99 89 320-222 None S27L 1037 156  96 — — — 320-223 None S27W 1061 143  66 — — — 320-224 None S27Y 1055 198 153 — — — 320-225 None S27aA 1066 267 243 — — — 320-226* None S27aQ 1035 250 228 — — — 320-227 None S27aD 1022 242 218 — — — 320-228 None S27aH 1072 259 235 — — — 320-229* None S27aK 1057 268 251 — — — 320-230 None S27aL 1087 245 223 — — — 320-231 None S27aW 1078 271 243 — — — 320-232 None S27aY 1051 261 235 — — — 320-233 None D27bA 1118 255 235 409 48 16 320-234 None D27bS 1089 262 239 — — — 320-235 None D27bQ 1110 256 236 — — — 320-236 None D27bH 1085 254 232 415  5  6 320-237 None D27bK 1073 240 221 398 10  8 320-238 None D27bL 1106 221 191 — — — 320-239 None D27bW 1079 212 163 — — — 320-240 None D27bY 1089 230 196 — — — 320-241* None I27cA 1092 179 122 — — — 320-242 None 127cS 1076 124  49 — — — 320-243 None I27cQ 1065  71  26 — — — 320-244* None I27cD 1083  21  20 — — — 320-245* None I27cH 1084  59  26 — — — 320-246 None I27cK 1089  32  23 — — — 320-247 None I27cL 1078 205 162 — — — 320-248 None I27cW 1110  96  30 — — — 320-249 None I27cY 1096  77  28 — — — 320-250 None G28A 1104 180 115 — — — 320-251 None G28S 1085 134  50 — — —

TABLE 5 SPR experiment - Run 3 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Supernatant 320-252 None G28Q 996 20 9 320-253 None G28D 1073 6 6 320-254 None G28H 1021 17 8 320-255 None G28K 842 24 8 320-256 None G28L 1055 30 10 320-257 None G28W 981 83 18 320-258 None G28Y 823 9 6 320-259 None A29S 824 194 179 320-260 None A29Q 836 182 165 320-261 None A29D 956 86 29 320-262 None A29H 891 209 190  320-263* None A29K 848 121 123 320-264 None A29L 831 199 184 320-265 None A29W 1057 168 69 320-266 None A29Y 934 218 192  320-267* None G30A 1148 299 297 320-268 None G30S 392 28 7 320-269 None G30Q 764 126 93 320-270 None G30D 511 9 5 320-271 None G30H 1067 106 30 320-272 None G30K 935 5 5 320-273 None G30L 710 4 4 320-274 None G30W 796 12 7 320-275 None G30Y 751 44 10 320-276 None L31A 1273 244 215  320-277* None L31S 1741 387 361  320-278* None L31Q 1696 389 374 320-279 None L31D 561 144 128  320-280* None L31H 881 228 211 320-281 None L31K 321 22 6 320-282 None L31W 811 75 16 320-283 None L31Y 317 2 3 320-284 None G32A 374 1 2 320-285 None G32S 400 1 2 320-286 None G32Q 576 1 4 320-287 None G32D 339 0 2 320-288 None G32H 422 1 3 320-289 None G32K 463 1 3 320-290 None G32L 361 1 2 320-291 None G32W 414 2 3 320-292 None G32Y 423 111 94 320-293 None V33A 421 104 86 320-294 None V33S 419 79 61 320-295 None V33Q 414 109 94 320-296 None V33D 428 118 104  320-297* None V33H 420 95 77 320-298 None V33K 416 114 100 320-299 None V33L 420 51 13 320-300 None H34W 417 111 95 320-301 None H34Y 456 108 96  320-302* None H34A 423 99 74 320-303 None H34S 408 71 32 320-304 None H34Q 401 103 82 320-305 None H34D 424 34 10 320-306 None H34K 452 147 133  320-307* None H34L 873 216 200 320-308 None H34W 458 106 73 320-309 None H34Y 255 47 40 320-310 None Q89A 348 70 62 320-311 None Q89S 0 0 0 *indicates antibodies that were selected for potency assay testing.

TABLE 6 SPR experiment - Run 4 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179 None None 616 177 163 320-312 None Q89D 529 10 10  320-313* None Q89H 502 141 132  320-314* None Q89K 598 165 158 320-315 None Q89L 515 85 82 320-316 None Q89W 535 65 62 320-317 None Q89Y 570 86 83  320-318* None S90A 578 160 149 320-319 None S90Q 523 18 14 320-320 None S90D 534 31 17 320-321 None S90H 491 16 13 320-322 None S90K 450 17 14 320-323 None S90W 490 14 13 320-324 None S90Y 528 13 12 320-325 None Y91A 491 95 83  320-326* None Y91S 550 126 120 320-327 None Y91Q 493 130 119  320-328* None Y91H 542 155 146 320-329 None Y91K 600 9 11 320-330 None Y91L 600 139 119  320-331* None Y91W 615 173 176 320-332 None D92A 531 66 44 320-333 None D92S 559 95 67 320-334 None D92Q 543 15 14 320-335 None D92H 581 15 14 320-336 None D92K 484 11 11 320-337 None D92L 475 21 15 320-338 None D92W 548 9 11 320-339 None D92Y 509 10 11 320-340 None G93A 548 145 132 320-341 None G93S 560 149 135 320-342 None G93Q 560 152 139 320-343 None G93D 545 121 90 320-344 None G93H 529 117 87  320-345* None G93K 637 163 154 320-346 None G93L 526 126 107 320-347 None G93W 560 149 130 320-348 None G93Y 541 144 127 320-349 None T94A 556 112 88 320-350 None T94S 502 130 118 320-351 None T94Q 553 112 83 320-352 None T94D 568 101 63 320-353 None T94H 558 97 73 320-354 None T94K 536 53 30 320-355 None T94L 526 102 76 320-356 None T94W 486 109 86 320-357 None T94Y 563 119 91 320-358 None L95A 501 82 50 320-359 None L95S 503 57 27 320-360 None L95Q 554 86 53  320-361* None L95D 477 12 11 320-362 None L95H 522 8 9 320-363 None L95Y 566 17 16 320-364 None S95aA 516 124 109 320-365 None S95aQ 536 141 128 320-366 None S95aD 487 62 31 320-367 None S95aH 595 119 116 320-368 None S95aK 602 50 26 320-369 None S95aL 503 89 60 320-370 None S95aW 570 66 39 320-371 None S95aY 576 92 70 *indicates antibodies that were selected for potency assay testing.

TABLE 7 SPR experiment - Run 5 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Supernatant 320-179 None None 83 11 10 320-372 None A96S 106 1 0 320-373 None A96Q 99 −1 −1 320-374 None A96D 98 1 0 320-375 None A96H 108 −2 −1 320-376 None A96K 98 3 1 320-377 None A96L 101 −1 −1 320-378 None A96W 105 −1 −1 320-379 None A96Y 105 3 1 320-380 None L97A 104 1 1 320-381 None L97S 97 3 1 320-382 None L97Q 106 0 0 320-383 None L97D 102 3 1 320-384 None L97H 98 3 2 320-385 None L97K 108 1 1 320-386 None L97W 104 1 0 320-387 None L97Y 97 11 10 320-388 G26A None 110 14 13 320-389 G26S None 105 12 11 320-390 G26Q None 100 12 11 320-391 G26D None 106 14 13 320-392 G26H None 109 12 11 320-393 G26K None 100 12 11 320-394 G26L None 106 13 12 320-395 G26W None 104 13 12 320-396 G26Y None 104 12 11 320-397 Y27A None 109 12 12 320-398 Y27S None 110 12 11 320-399 Y27Q None 105 10 10 320-400 Y27D None 106 11 11 320-401 Y27H None 100 11 10 320-402 Y27L None 98 11 10 320-403 Y27W None 84 11 10 320-404 T28A None 84 11 10 320-405 T28S None 79 10 9 320-406 T28Q None 82 8 7 320-407 T28D None 88 12 11 320-408 T28H None 81 13 12 320-409 T28K None 83 10 10 320-410 T28L None 86 11 10 320-411 T28W None 82 10 9 320-412 T28Y None 89 10 9 320-413 F29A None 89 9 8 320-414 F29S None 78 7 7 320-415 F29Q None 85 5 4 320-416 F29D None 81 9 8 320-417 F29H None 85 9 8 320-418 F29K None 85 10 9 320-419 F29L None 83 11 9 320-420 F29W None 85 11 10 320-421 F28Y None 81 9 8 320-422 T30A None 80 10 9 320-423 T30S None 86 10 10 320-424 T30Q None 86 11 10 320-425 T30D None 89 14 12 320-426 T30H None 84 10 9 320-427 T30K None 88 11 10 320-428 T30L None 88 11 10 320-429 T30W None 90 12 11 320-430 T30Y None 85 6 6 320-431 S31A None 85 6 6

TABLE 8 SPR experiment - Run 6 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179 None None 449 111 102 320-432 S31Q None 466 116 106 320-433 S31D None 412 90 83 320-434 S31K None 473 125 113 320-435 S31L None 384 92 83 320-436 S31W None 525 129 118 320-437 S31Y None 501 119 109 320-438 Y32A None 468 126 116 320-439 Y32S None 464 119 108 320-440 Y32Q None 408 108 97 320-441 Y32D None 388 80 67 320-442 Y32H None 490 124 113  320-443* Y32K None 438 114 103 320-444 Y32L None 458 107 95  320-445* Y32W None 442 116 106 320-446 D33A None 469 18 8 320-447 D33S None 503 37 13 320-448 D33Q None 482 7 6 320-449 D33H None 483 76 59 320-450 D33K None 536 1 3 320-451 D33L None 497 19 8 320-452 D33W None 445 84 78 320-453 D33Y None 449 111 104 320-454 I34A None 189 43 37 320-455 I34S None 144 27 23 320-456 I34Q None 214 52 46 320-457 I34D None 55 6 4 320-458 I34H None 239 59 53 320-459 I34K None 93 20 17 320-460 I34L None 441 114 105 320-461 I34W None 465 87 82 320-462 I34Y None 373 58 52  320-463* N35A None 462 102 101  320-464* N35S None 600 130 124 320-465 N35Q None 476 92 78 320-466 N35D None 360 93 86 320-467 N35H None 350 44 24 320-468 N35K None 200 2 2 320-469 N35L None 315 69 61 320-470 N35W None 329 2 3 320-471 N35Y None 312 3 4 320-472 None S90L 467 23 10 320-473 None Y91D 453 69 55 320-474 None L95K 596 2 4 320-475 None L95W 727 8 8 320-476 Y27K None 560 128 118  320-477* S31H None 576 148 136 320-478 A60L None 379 85 77 320-479 A60W None 277 61 54 320-480 A60Y None 319 79 73 320-483 W50A None 492 4 6 320-484 W50S None 555 3 6 320-485 W50Q None 460 3 5 320-486 W50D None 178 1 2 320-487 W50H None 237 2 3 320-488 W50K None 293 1 2 320-489 W50L None 337 4 5 320-490 W50Y None 393 14 8 320-491 L51S None 356 85 76 *indicates antibodies that were selected for potency assay testing.

TABLE 9 SPR experiment - Run 7 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179 None None 301 61 56 320-492 L51Q None 439 89 82 320-493 L51D None 242 48 46 320-494 L51H None 811 150 138 320-495 L51K None 466 84 77 320-496 L51W None 581 93 87 320-497 N52A None 727 135 125 320-498 N52S None 485 90 82 320-499 N52Q None 551 122 113 320-500 N52D None 472 69 53 320-501 N52H None 533 118 108 320-502 N52K None 659 88 59 320-503 N52W None 484 41 6 320-504 N52Y None 500 88 65 320-505 P52aA None 570 118 110 320-506 P52aS None 444 97 89 320-507 P52aQ None 181 27 24 320-508 P52aD None 203 19 12 320-509 P52aH None 290 52 47 320-510 P52aK None 289 44 33 320-511 P52aL None 581 106 98 320-512 P52aW None 746 126 118 320-513 P52aY None 585 99 90 320-514 N53A None 516 96 88 320-515 N53S None 375 73 67 320-516 N53Q None 461 92 86 320-517 N53D None 493 55 50 320-518 N53H None 882 169 153 320-519 N53K None 993 217 196 320-520 N53L None 1016 174 162 320-521 N53W None 830 166 152 320-522 N53Y None 693 141 129 320-523 S54A None 476 88 82 320-524 S54Q None 292 55 49 320-525 S54D None 437 33 17 320-526 S54H None 672 134 124 320-527 S54K None 578 146 136 320-528 S54L None 829 121 108 320-529 S54W None 605 94 83 320-530 S54Y None 425 77 67 320-531 G55A None 331 66 61 320-532 G55S None 648 10 7 320-533 G55Q None 441 93 86 320-534 G55D None 647 109 102 320-535 G55H None 637 126 115 320-536 G55K None 553 115 105 320-537 G55L None 717 133 123 320-538 G55W None 318 54 49 320-539 N56A None 859 172 159 320-540 N56S None 500 100 92 320-541 N56Q None 504 94 84 320-542 N56D None 839 97 86 320-543 N56H None 597 138 126 320-544 N56K None 690 120 112 320-545 N56L None 518 109 100 320-546 N56W None 341 67 61  320-547* N56Y None 318 77 75 320-548 T57A None 335 74 68 320-549 T57S None 269 50 45 320-550 T57Q None 635 112 103 320-551 T57D None 280 44 36 320-552 T57H None 595 104 97 320-553 T57K None 494 84 78 320-554 T57L None 506 66 51 320-555 T57W None 674 62 30 320-556 T57Y None 634 100 90 320-557 G58A None 378 26 6 320-558 G58S None 463 3 2 320-559 G58Q None 535 9 5 320-560 G58D None 907 36 9 320-561 G58H None 539 14 6 320-562 G58K None 326 2 1 320-563 G58L None 258 2 2 320-564 G58W None 345 72 67 320-565 G58Y None 545 43 12 320-566 Y59A None 720 120 110 320-567 Y59S None 590 96 86 320-568 Y59Q None 688 115 107 320-569 Y59D None 408 79 73 320-570 Y59H None 435 79 72 320-571 Y59K None 394 78 72 320-572 A60S None 459 98 90 320-573 A60Q None 338 67 62 320-574 A60D None 693 140 130 320-575 A60H None 581 121 110 320-576 A60K None 479 90 83 320-577 L51A None 479 98 90 320-578 L51Y None 415 83 77 320-579 N52L None 214 46 41 320-580 G55Y None 261 51 47 320-581 Y59L None 337 70 65 320-582 Y59W None 453 67 52 *indicates antibodies that were selected for potency assay testing.

TABLE 10 SPR experiment - Run 8 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179  None None 402 98 86 320-583* None G30A, Y91W 404 108 103 320-584* None L31S, Y91W 399 103 98 320-585* None L31Q, Y91W 406 116 109 320-586* None H34L, Y91W 405 108 103 320-587* N56Y Y91W 402 123 122 320-588* N56Y G30A 409 128 123 320-589* N56Y L31S 399 120 109 320-590* N56Y L31Q 405 130 121 320-591* N56Y H34L 399 132 124 320-592* N56Y G30A, Y91W 408 128 129 320-593* N56Y L31S, Y91W 405 126 124 320-594* N56Y L31Q, Y91W 407 134 132 320-595* N56Y H34L, Y91W 403 129 128 *indicates antibodies that were selected for potency assay testing.

TABLE 11 SPR experiment - Run 9 - Anti-TL1A antibodies binding to TL1A. TL1A TL1A VH VL Binding Binding Substitution Substitution Capture Level Level relative to relative to Level (Early) (Late) Antibody 320-179 320-179 Purified Antibody 320-179 None None 402 108 98 320-596 None Y91F 405 95 85 320-597 None L31Q, Y91F 401 115 105 320-598 None H34L, Y91F 403 112 101 320-599 None L31S, Y91F 411 113 103 320-600 None G30A, Y91F 399 111 104  320-601* N56Y Y91F 409 121 120 320-602 N56Y L31Q, Y91F 399 131 125 320-603 N56Y H34L, Y91F 394 126 118 320-605 N56Y G30A, Y91F 399 125 120  320-611* N56Y Y91W, G93K 397 125 127 320-612 None Y91W, G93Y 400 126 120  320-613* N56Y Y91W, G93Y 408 135 131 320-614 N56Y G93K 401 122 111 320-615 N56Y G93Y 393 113 108 320-616 N56Y G93A 396 120 112 *indicates antibodies that were selected for potency assay testing.

Antibodies that had capture levels similar or better than 320-179 as well as a TL1A Binding Level (Early) and TL1A Binding Level (Late) values that were in a similar range were taken forward into potency assays. These variants are indicated by shading in Tables 3-11. A comparison of the off-rate as measured by SPR for several of the antibodies is shown in FIG. 5. Several of the antibodies dissociated at a slower rate than that of the parental antibody 320-179.

2.2 Anti-TL1A antibodies with improved potency in cell based assay. To assess if improved off-rate correlated with an enhanced potency purified antibody, variants were run in the TL1A induced caspase activity assay in TF-1 cells. Potent antibodies act by binding to TL1A and inhibiting TL1A activation of the DR3 receptor. This receptor triggers an apoptosis pathway in which caspases are activated and can be detected using commercial reagents. In each experiment the antibody variant was compared to 320-179 for fold improvement in potency. The results are shown in Table 12.

TABLE 12 TL1A induced caspase potency assay in TF-1 cells: Inhibition by anti-TL1A antibodies. VH VL Substitution Substitution Antibody 320-179 Fold relative to relative to IC₅₀ IC₅₀ improve- Antibody 320-179 320-179 (μg/mL) (μg/mL) ment 320-184 None L79A 0.010 0.030 3 320-185 None L79S 0.020 0.030 2 320-186 None L79Q 0.030 0.030 1 320-187 None L79D 0.020 0.040 2 320-188 None L79H 0.010 0.040 4 320-189 None L79K 0.110 0.040 0 320-190 None L79W 0.020 0.040 2 320-191 None L79Y 0.020 0.040 2 320-198 None T24L 0.010 0.010 1 320-201 None S25A 0.005 0.010 2 320-202 None S25Q 0.010 0.010 1 320-205 None S25K 0.020 0.030 2 320-207 None S25W 0.007 0.020 3 320-209 None S26A 0.040 0.020 1 320-211 None S26D 0.010 0.030 3 320-213 None S26K 0.070 0.030 0 320-219 None S27D 0.020 0.030 2 320-226 None S27aQ 0.030 0.020 1 320-229 None S27aK 0.040 0.060 2 320-241 None I27cA 0.020 0.010 1 320-244 None I27cD 5.030 0.010 0 320-245 None I27cH 0.540 0.010 0 320-263 None A29K 0.003 0.010 3 320-267 None G30A 0.010 0.040 4 320-277 None L31S 0.003 0.010 3 320-278 None L31Q 0.010 0.020 2 320-280 None L31H 0.006 0.020 3 320-297 None V33H 0.005 0.020 4 320-302 None H34A 0.010 0.020 2 320-307 None H34L 0.010 0.040 4 320-313 None Q89H 0.020 0.030 2 320-314 None Q89K 0.020 0.030 2 320-318 None S90A 0.020 0.050 3 320-326 None Y91S 0.030 0.050 2 320-328 None Y91H 0.020 0.020 1 320-331 None Y91W 0.002 0.020 10 320-345 None G93K 0.020 0.010 1 320-361 None L95D 0.010 0.010 1 320-443 Y32K None 0.060 0.060 1 320-445 Y32W None 0.030 0.060 2 320-463 N35A None 0.020 0.050 3 320-464 N35S None 0.030 0.050 2 320-477 S31H None 0.030 0.040 1 320-547 N56Y None 0.004 0.040 10 320-583 None G30A, Y91W 0.003 0.080 27 320-584 None L31S, Y91W 0.008 0.080 10 320-585 None L31Q, Y91W 0.003 0.040 13 320-586 None H34L, Y91W 0.002 0.050 25 320-587 N56Y Y91W 0.001 0.040 40 320-588 N56Y G30A 0.004 0.020 5 320-589 N56Y L31S 0.020 0.020 1 320-590 N56Y L31Q 0.006 0.020 3 320-591 N56Y H34L 0.002 0.020 10 320-592 N56Y G30A, Y91W 0.003 0.020 7 320-593 N56Y L31S, Y91W 0.004 0.060 15 320-594 N56Y L31Q, Y91W 0.005 0.060 12 320-595 N56Y H34L, Y91W 0.003 0.060 20 320-601 N56Y Y91F 0.002 0.020 10 320-611 N56Y Y91W, G93K 0.005 0.040 8 320-613 N56Y Y91W, G93Y 0.010 0.040 4 ** Several of the antibodies with fold improvements greater than 10 fold improvement in in this potency were run in up to n = 7 assays. Results were consistent with the data shown table. FIG. 7 shows n = 4 replicates of several of the antibodies with improved potency compared to 320-179.

As demonstrated in Table 12 and in FIG. 6, several of the single substitution antibodies tested had superior potency compared to 320-179. Of all the single substitution antibody variants tested two had greater than 10 fold improvement in potency when compared to 320-179. These variants were 320-331 (which contained a Y91W substitution in the variable light chain) and 320-547 (which contained a N56Y substitution in the variable heavy chain) (FIG. 6). This result is unexpected, as typically CDR3 of the antibody VH is dominantly involved in antibody binding, while in contrast, the N56Y substitution that was identified has substantial influence on binding lies in CDR2 of the antibody VH. When variants were made incorporating either Y91W from the VL or separately N56Y in the VH with other substitutions that improved the potency, highly potent antibodies were obtained. When the Y91W VL substitution was combined with the N56Y VH substitution into one antibody, 320-587, the fold improvement in potency compared to 320-179 was 40. FIG. 7 shows four different repeat experiments demonstrating the potency increase of four antibodies 320-587, 320-591, 320-592, and 320-601 compared to 320-179. The sequences of these antibodies with improved potency compared to 320-179 are shown in FIG. 3 (variable heavy chain) and FIG. 4 (variable light chain).

A comparison of the potency of 320-587 compared to other previously described anti-TL1A antibodies was performed. These previously described antibodies include antibody 1681N described in U.S. Pat. No. 8,642,741 (VH is SEQ ID NO: 18; VL is SEQ ID NO. 26), antibody VH5/VL1 from U.S. Publ. No. 2014/0308271 (VH is SEQ ID NO: 24; VL is SEQ ID NO: 17), humanized 1B4 as described in U.S. Pat. No. 8,263,743 (VH is SEQ ID NO: 74; VL is SEQ ID NO: 75) and 320-168 (also called C320-168) as described in U.S. Publ. No. 2014/0255302A1 (VH is SEQ ID NO: 181; VL is SEQ ID NO: 194). FIG. 8 shows that 320.587 has superior potency in the cell based assay compared to these previously described antibodies, making it the most potent anti-TL1A antibody described.

2.3. DR3 and DcR3 receptor competition assays. Antibodies that displayed increased potency compared to 320-179 were screened for their ability to inhibit TL1A binding to its cognate signalling receptor, DR3, or a decoy receptor, DcR3. All anti-TL1A antibodies tested showed inhibition of TL1A binding to DR3, when compared to an isotype control (FIG. 9). This confirms that the antibodies inhibit TL1A activity by blocking the TL1A-DR3 interaction.

In previous experiments described in U.S. Publ. No. 2014/0255302A1 (Example 4), antibody 320-179 (320-179) was tested in receptor competition assay and shown to selectively inhibit the binding of TL1A to DR3 by not to DcR3 (FIG. 10). In experiments presented herein in FIG. 10 it is again shown that 320-179 does not inhibit the TL1A-DcR3 interaction. This stands in contrast with the improved anti-TL1A antibodies tested. Antibodies with improved potency in the TF-1 cell assay (as described in Section 2.2), including antibody 320-587, consistency inhibited the TL1A-DcR3 interaction.

In summary, the parental antibody 320-179 was capable of inhibiting the TL1A-DR3 interaction but not the TL1A-DcR3 interaction. Several antibodies with improved potency such as 320-267 (VH is SEQ ID No: 1; VL is SEQ ID No: 11), 320-277 (VH is SEQ ID NO: 1, VL is SEQ ID NO 12), 320-278 (VH is SEQ ID NO 1; VL is SEQ ID NO 13) and 320-591 (VH is SEQ ID NO: 3, VL is SEQ ID NO 9) inhibited the TL1a-DR3 interaction but not the TL1A-DcR3 interaction. Several antibodies with improved potency such as 320-331, 320-547, 320-583, 320-584, 320-585, 320-586, 320-587 and variants of these antibodies, are capable of inhibiting both the TL1A-DR3 and the TL1A-DcR3 interaction.

2.4. Species cross-reactivity of 320-587 was tested for its ability to bind to recombinantly produced TL1A from different species. The antibody bound to TL1A from all species tested (FIG. 11). The binding of 320-587 to human, rat, guinea pig, dog, cat, cynomolgus monkey TL1A had a slow dissociation rate, indicating a high affinity interaction. The antibody bound mouse and rabbit TL1A and had a fast dissociation rate.

2.5. Pre-clinical efficacy models for testing anti-TL1A antibodies in the following animal models of disease:

Asthma: allergen-induced asthma—rodent (mouse, rat or guinea pig) is sensitized by intradermal injection of ovalbumin (OVA), especially OVA derived from chicken eggs, plus alum and then challenged at least 2 weeks later by aerosolized of nebulized OVA, causing asthma-like symptoms including airways hyerreactivity, influx of eosinophils and increased production of cytokines (e.g., Hylkema et al., 2002, Clin. Exp. Immunol. 129:390-96). Such a model could be modified by repeated challenge to present a more chronic disease profile with increased airways remodeling and fibrosis induction (e.g., Bos et al., 2007, Eur. Respir. J. 30:653-661). Alternative allergens, such as house dust mite, may also be used (e.g., Lambert et al., 1998, Am. J. Respir. Crit. Care Med. 157:1991-9). Alternatively, a nonhuman primate (e.g., cynomolgus macaque) may be sensitized and challenged with an environmental antigen such as Ascaris suum, leading to airways hyerreactivity, influx of eosinophils and increased production of cytokines (e.g., Wegner et al., 1991, J. Allergy Clin. Immunol 0.87:835-41).

COPD: Smoke inhalation-induced airways inflammation—rodent (mouse, rat or guinea pig) will be exposed to cigarette smoke 3-7 times a week for at least 4 weeks causing a pulmonary disease similar to COPD, characterized by lung accumulation of neutrophils, increased inflammatory cytokine production, lung fibrosis and pulmonary hypertension (e.g., Davis et al. (2012) PLoS One 7:e33304). A more severe form of disease may be induced by including repeat bacterial or viral infection into the lungs during smoke exposure (e.g., Li et al. (2012) Biol. Pharm. Bull. 35:1752-60). Rodents with smoke-induced COPD will be treated with anti-TL1A antibodies and screened for treatment efficacy.

Pulmonary fibrosis: Bleomycin-induced pulmonary fibrosis—rodent (mouse, rat or guinea pig) will be treated with bleomycin either by intratracheal/intranasal instillation or intravenous injection once or twice weekly for at least 3 weeks. This treatment induces significant and stable pulmonary fibrosis (e.g., Pinart et al. (2009) Resp. Physiol. Neurobiol. 166:41-46). Rodents with bleomycin-induced pulmonary fibrosis will be treated with anti-TL1A antibodies and screened for treatment efficacy.

Cystic Fibrosis: CFTR knockout ferret model—ferrets homozygous for gene knockout, or known disease-related mutations, of CFTR (causative gene in cystic fibrosis) spontaneously develop a cystic fibrosis-like disease characterized by mucus obstruction of airways, atelectasis, interstitial pneumonia and repeated lung infections with progressive lung bacterial colonization (e.g., Sun et al. (2014) Am. J. Respir. Cell Mol. Biol. 50:502-12). CFTR^(−/−) ferrets will be treated with anti-TL1a antibodies and screened for treatment efficacy.

Irritable Bowel Syndrome: Stress-induced visceral hypersensitivity—Stress will be induced in rats by either neonatal-maternal separation (e.g., Coutinho et al. (2002) Am. J. Physiol. Gastrointest. Liver Physiol. 282:G307-16) or restraint of adults (e.g., Shen et al. (2010) J. Neurogastroenterol. Motil. 16:281-90). This is expected to produce altered colonic motility and visceral hypersensitivity similar to that observed in IBS patients. Stressed rats will be treated with anti-TL1A antibodies and screened for treatment efficacy.

Rheumatoid Arthritis: Collagen-induced arthritis—rodent (mouse, rat or guinea pig) will be immunized and boosted with collagen in adjuvant. Animals develop bilateral foot swelling and erythema, inflammatory infiltrate into joint area and joint damage (e.g., Bendele et al. (1999) Toxicol. Pathol. 27:134-42). Rodents with collagen-induced arthritis will be treated with anti-TL1A antibodies and screened for treatment efficacy.

Eosinophilic esophagitis: Intranasal Aspergillus fumigatus-induced eosinophilic esophagitis. Mice exposed to repeat intranasal instillation of A. fumigates develop marked esophageal eosinophilia, epithelial dysplasia and hyperplasia, and free eosinophil granules (e.g., Mishra et al. (2001) J. Clin. Invest. 107:83-90). Similarly, repeat aerosol exposure to ovalbumin over a two week period in sensitized guinea pigs causes esophageal eosinophilia with infiltration of both eosinophils and mast cells into the epithelial layer (e.g., Liu et al. (2015) Am. J. Physiol. Gastrointest. Liver Physiol. 308:G482-488). Mice or guinea pigs with eosinophilic esophagitis will be treated with anti-TL1A antibodies and screened for treatment efficacy.

2.6. Use of TL1A antibodies in detecting samples containing TL1A antibodies of the disclosure can be used to detect TL1A in human samples. 320-587 was used to detect human TL1A secreted from human PBMCs stimulated with immune complexes (FIG. 13) in ELISA format. 320-587 was also used to detect a population of human PBMCs that express membrane TL1A on their surface in flow cytometry experiments (FIG. 14).

2.7. Affinity measurements of Anti-TL1A antibody binding to human TL1A by kinetic exclusion assay. Time to reach equilibrium with 320-587 as CBP: First, the K_(on) rate for the 320-587/TL1A interaction was measured. Briefly, a solution was prepared by mixing 320-587 and TL1A, and aliquots were removed at various time points over 3 hours. Free 320-587 was captured by passing the solution over a column packed with Sepharose beads coated with 20 μg/mL TL1A. Captured 320-587 was detected with an Alexa Fluor® 647-conjugated anti-human antibody (0.5 μg/mL). This assay was repeated two times yielding K_(on) rates of 8.35×10⁵ Ms⁻¹ and 7.45×10⁵ Ms⁻¹, with an average K_(on) rate of 7.90×10⁵ Ms⁻¹. The K_(on) rate was then used to estimate the amount of time required to reach equilibrium at various concentrations of 320-587 using the theoretical binding curve tool provided on the Sapidyne website (www.Sapidyne.com).

KD determination with 320-587 as CBP. The CBP, 320-587, was diluted in assay buffer (DPBS supplemented with 1 mg/ml BSA) to final concentrations of 15, 50 and 150 pM. The titrant, human TL1A was diluted in assay buffer to create a concentration series of 0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 and 3000 pM. Using the time to reach equilibrium determined above, curves that contained either 50 or 150 pM 320-587 were allowed to come to equilibrium in a 25° C. incubator for 2 days. Curves that contained 15 pM 320-587 were allowed to come to equilibrium in a 25° C. incubator for 3 days. Following the equilibration period, the free fraction of 320-587 in each reaction was quantitated as described in above. The K_(D) values were determined using n-curve analysis of equilibrium curves generated with 15, 50 and 150 pM 320-587.

Time to reach equilibrium with TL1A as CBP: The time to reach equilibrium in this orientation was estimated using the K_(on) for the 320-587/TL1A interaction, determined as described in 2.8 above. In this format, the free fraction of TL1A was captured by passing the solution over a column packed with PMMA beads coated with 30 μg/mL 320-587. Captured TL1A was detected with an anti 6×-his DyLight 650 antibody (0.75 μg/mL). This assay was repeated two times yielding K_(on) rates of 6.11×10⁵ Ms⁻¹ and 5.74×10⁵ Ms⁻¹, with an average K_(on) rate of 5.93×10⁵ Ms⁻¹.

K_(D) determination with TL1A as CBP: The CBP, human TL1A, was diluted in assay buffer to final concentrations of 30, 100 and 300 pM. The titrant, 320-587, was diluted in assay buffer to create a concentration series of 0.05, 0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 pM.

Using the time to reach equilibrium determined above, all curves were allowed to come to equilibrium in a 25° C. incubator for 3 days. Following the equilibration period, the free fraction of TL1A in each reaction was quantitated as described above. The K_(D) values were determined using n-curve analysis of equilibrium curves generated with 30, 100 and 300 pM TL1A.

Good agreement was observed between the two KinExA methods as well as a relatively low % error. The K_(D) value for the interaction of TL1A with 320-587 determined using 320-587 as the CBP was 40.97±8.33 pM (Table 13), while the K_(D) obtained using TL1A as the CBP was 41.52±13.5 pM (Table 14).

TABLE 13 Affinity: Sepharose beads coated with TL1A; 320-587 as the CBP. Assay No: K_(D) (pM) % Error 1 40.43 4.57 2 52.03 5.61 3 46.31 4.76 4 32.42 3.74 5 33.66 3.9 Average 40.97 SD 8.33 % CV 20

TABLE 14 Affinity: PMMA beads coated with 320-587; TL1A as the CBP. Assay No: K_(D) (pM) % Error 1 33.39 5.33 2 57.1 5.51 3 34.07 3.9 Average 41.52 SD 13.5 % CV 33

3.0. Preclinical Efficacy Models for Testing Anti-TL1a Antibodies.

3.0.1. Asthma.

Acute ovalbumin-induced asthma in rats. Brown-Norway rats were sensitized with OVA by i.p. injection on day 0 then challenged with OVA aerosol daily on days 35-42. Rats were treated with antibody 320-587 or vehicle by i.v. injection on days 14, 21, 28 and 35. Bronchoalveolar lavage fluid (BALF) was assessed for total and differential cells on day 43. Treatment was found to significantly reduce BALF eosinophils (FIG. 15).

Chronic ovalbumin-induced asthma in rats. Rats were sensitized with OVA plus alum by i.p. injection on days 0 and 7, and then challenged with OVA aerosol twice weekly for 3 weeks starting on day 14 through day 31, and on 5 consecutive days from days 37 to 42. Animals were treated with antibody 320-587 or vehicle i.v. on days 24, 29, 34 and 39. BALF was assessed for total and differential cells, and a panel of cytokines on day 43. Lung sections were stained with hematoxylin and eosin (H&E), and periodic-acid Schiff (PAS), and assessed for a range of pathologies. Treatment with 320-587 significantly decreased BALF eosinophils and macrophages (FIGS. 17A and 17B), BALF IL-4 and IL-13 (FIG. 17C), goblet cell hyperplasia (FIG. 17D) and the thickness of the bronchial epithelial layer (FIG. 17E), compared to the vehicle.

Acute ovalbumin-induced asthma in guinea pigs. Male Dunkin Hartley guinea pigs were sensitized to ovalbumin and thereafter underwent surgery to install a balloon catheter to measure lung function and early and late asthmatic reactions. On day 16, 20, 24 and 28, animals were treated i.p. with antibody 320-587 or vehicle. Challenge with ovalbumin (0.05-0.1%) aerosol was performed 30 minutes after the last treatment. Airway responsiveness (AHR) to histamine was measured 24h before challenge, 6h after challenge (directly after the early asthmatic reaction) and 24 h after challenge (directly after the late asthmatic reaction). The nature and size of the early and late asthmatic reactions was also be recorded by online registration of lung function over the entire 24 h period. Animals were sacrificed 25h after challenge and bronchoalveolar lavage performed. BALF was assessed for total and differential cells. Treatment with 320-587 significantly decreased both eosinophils and macrophages in BALF (FIGS. 16A and 16B) as well as ameliorating AHR after the early asthmatic reaction (FIG. 16C) and the overall magnitude of the early asthmatic reaction (FIG. 16D), as compared to vehicle.

Chronic ovalbumin-induced asthma in guinea pigs. Male Dunkin Hartley guinea pigs were sensitized to ovalbumin, and 4 weeks thereafter challenged with ovalbumin weekly for 12 weeks. Ovalbumin challenge (0.05-0.5%) was performed by inhalation of aerosolized solution until airway obstruction was observed. Animals were treated with antibody 320-587 or vehicle i.p. every 5 days starting week 8 of ovalbumin challenges. Airways function, by means of airways responsiveness to histamine, was measured before the initial challenge, 24 hours before the final challenge, and 6 hours after the final challenge. Although no effect on AHR induced by histamine challenge was observed, antibody 320-587 significantly decreased the allergic response to OVA, as progressively increasing doses of OVA were required to induce airways obstruction (FIG. 18).

The differences in antibody therapeutic effect observed in the acute and chronic asthma models in guinea pigs is believed to be a function of the model itself. It is believed that in the chronic model, the degree of AHR decreases over time and, accordingly, becomes less responsive to treatment. In the art, the acute model is generally used to observe compound effects on airways responsiveness, and the chronic model is generally used to observe compound effects on airways remodelling. Remodelling assessments are ongoing. Nevertheless, it was surprising to observe the antibodies having an impact on the response to allergen—although the antibody didn't substantially impact absolute AHR (response to histamine) at this stage, it had significantly decreased the direct allergic response to antigen.

3.0.2. Inflammatory Bowel Disease

TNBS-induced colitis in rats: Rats were treated with a single dose of tri-nitrobenzenesulfonic acid in ethanol by intrarectal instillation dose. Control animals received equivalent volume of ethanol only. Over a space of 7 days, animals developed focal colitis characterized by ulceration of the colon with inflammatory infiltrate and varying degrees of fibrosis (e.g., Wirtz et al. (2007) Nat. Protoc. 2:541-546). 320-587 administration significantly reduced multiple disease indicators including colon thickness (FIG. 12A), number and severity of adhesions (FIG. 12B), and number and severity of strictures (FIG. 12C) leading to a significantly milder disease than animals treated with either vehicle or an isotype-matched irrelevant antibody (FIG. 12D). Decreased colon fibrosis (FIG. 19) was also observed in 320.587 treated animals.

Comparison of disease after 7 and 14 days in DNBS-induced colitis in rats. Colitis was induced as described above using dinitrobenzenesulfonic acid (DNBS) instead of TNBS, and the rats used in the DNBS experiments were Wistar rats. Animals were treated with antibody 320-587 or vehicle i.v. on days 1 and 8. Groups were assessed for colitis 7 and 14 days post-DNBS and disease severity compared between the two timepoints. Treatment with antibody 320-587 had limited effect on day 7, but by day 14, animals treated with antibody 320-587 showed significant improvement in colon weight and length (FIG. 20A), fibrosis (FIG. 20B), inflammatory infiltrate (FIG. 20C) and colon damage (FIG. 20D). Representative sections of ulcer area colon (FIG. 20E) show the extent of damage repair and reduction in fibrosis at 14 days. At both 7 and 14 days, vehicle-treated animals showed extensive inflammatory infiltrate and fibrosis with significant loss of intestinal architecture. In contrast, 320-587-treated animals showed significant inflammatory infiltrate, fibrosis and loss of intestinal architecture at 7 days but these effects are largely reversed by 14 days.

The differences observed in the antibody therapeutic effects observed in the TNBS and DNBS models are believed to arise from the use of different strains of rats (Sprague-Dawley for TNBS versus Wistar for DNBS). Each rat strain has differences in their responses to immunological challenges such that the kinetics of their response in these models is believed to be different. As well, TNBS and DNBS are different structurally, and are believed to induce variations in the disease state.

Chronic (21 day) DSS-induced colitis in rats. Rats were given dextran sulfate sodium (DSS) at a concentration of 5% w/v in drinking water for 7 days, then 2% w/v in drinking water for a further 14 days. Animals developed diarrhea, diffuse colonic inflammation, goblet cell hyperplasia, and crypt epithelial damage and ulceration (e.g. Randhawa et al. (2014) Korean J. Physiol. Pharmacol. 18:279-88). Rats were treated with antibody 320-587 or vehicle by intravenous injection on days 5, 12 and 19. Animals were weighed and assessed for clinical disease (diarrhea and occult blood) daily, and colon weight and length were assessed on day 21. Antibody 320-587 treatment significantly reversed DSS-induced slowdown of weight gain (FIG. 21A), ameliorated clinical signs of disease (FIG. 21B) and improved colon weight and length (FIG. 21C).

Induction of intraperitoneal cytokines by recombinant human TL1A. Intraperitoneal injection of recombinant mouse TL1A can induce the production of inflammatory cytokines such as IL-5. In this study, mice received a single dose of either antibody 320-587 or vehicle then an hour later were treated with recombinant human TL1A (rhTL1A) 40 μg/mouse. Six hours after rhTL1A dosage, peritoneal lavage was performed and the peritoneal fluid assessed for cytokines and chemokines by multiplex assay. Treatment with antibody 320-587 significantly decreased peritoneal concentrations of cytokines G-CSF, IL-1b, IL-5, IL-6, IL-17, and chemokines IP-10, KC, MCP-1, MIP-1a, MIP-1b, MIP-2 (FIG. 22).

The disclosure is not limited to the embodiments described and exemplified above, but is capable of variation and modification within the scope of the appended claims. 

1-25. (canceled)
 26. A method for treating a gastrointestinal disease, comprising administering to a subject in need of treatment for a gastrointestinal disease a recombinant antibody, comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:
 22. 27. The method according to claim 26, wherein the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, irritable bowel syndrome, or a gastrointestinal disease associated with cystic fibrosis.
 28. A method for treating arthritis, comprising administering to a subject in need of treatment for arthritis a recombinant antibody, comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 30, provided that when the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2, wherein the antibody specifically binds to TNF-Like ligand 1A (TL1A) and wherein the antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3).
 29. (canceled)
 30. A method for treating a skin disease, comprising administering to a subject in need of treatment for a skin disease a recombinant antibody, comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 28, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 30, provided that when the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the light chain variable region does not comprise the amino acid sequence of SEQ ID NO: 2, wherein the antibody specifically binds to TNF-Like ligand 1A (TL1A) and wherein the antibody is capable of inhibiting the interaction of TL1A with the death receptor 3 (DR3).
 31. (canceled)
 32. A method for treating a gastrointestinal disease, comprising administering to a subject in need of treatment for a gastrointestinal disease a recombinant antibody, comprising a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 15, a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 21, a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 19, and a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:
 30. 33. The method according to claim 26, wherein the heavy chain variable region CDR2 comprises the amino acid sequence of SEQ ID NO:
 16. 34. The method according to claim 32, wherein the light chain variable region CDR3 comprises the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO:
 27. 35. The method according to claim 32, wherein the light chain variable region CDR3 comprises the amino acid sequence of SEQ ID NO:
 22. 36. The method according to claim 32, wherein the light chain variable region CDR1 comprises the amino acid sequence of SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26, and the light chain variable region CDR3 comprises the amino acid sequence of SEQ ID NO:
 22. 37. The method according to claim 26, wherein the heavy chain variable region CDR2 comprises the amino acid sequence of SEQ ID NO: 21 and the light chain variable region CDR1 comprises the amino acid sequence of SEQ ID NO:
 18. 38. The method according to claim 37, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
 4. 39. The method according to claim 37, wherein the antibody comprises a human IgG1 heavy chain constant region.
 40. The method according to claim 37, wherein the antibody comprises a human light chain lambda constant region.
 41. The method according to claim 37, wherein the antibody comprises a human IgG1 heavy chain constant region and a human light chain lambda constant region.
 42. The method according to claim 38, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:
 61. 43. The method according to claim 38, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:
 60. 44. The method according to claim 38, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 60 and a light chain comprising the amino acid sequence of SEQ ID NO:
 61. 45. The method according to claim 32, wherein the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, irritable bowel syndrome, or a gastrointestinal disease associated with cystic fibrosis.
 46. The method according to claim 37, wherein the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, irritable bowel syndrome, or a gastrointestinal disease associated with cystic fibrosis.
 47. The method according to claim 38, wherein the gastrointestinal disease is inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, eosinophilic esophagitis, irritable bowel syndrome, or a gastrointestinal disease associated with cystic fibrosis. 